Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG daily Stock Chart
CRISPR Therapeutics AG
Index- P/E92.76 EPS (ttm)0.75 Insider Own0.40% Shs Outstand60.85M Perf Week14.49%
Market Cap4.14B Forward P/E- EPS next Y-5.20 Insider Trans-27.56% Shs Float48.24M Perf Month33.27%
Income45.50M PEG- EPS next Q-0.98 Inst Own60.00% Short Float8.33% Perf Quarter34.60%
Sales289.40M P/S14.29 EPS this Y134.10% Inst Trans12.88% Short Ratio4.15 Perf Half Y3.74%
Book/sh14.56 P/B4.80 EPS next Y-11.00% ROA5.50% Target Price73.82 Perf Year90.00%
Cash/sh15.05 P/C4.65 EPS next 5Y- ROE6.50% 52W Range32.30 - 74.00 Perf YTD14.83%
Dividend- P/FCF104.43 EPS past 5Y54.00% ROI4.90% 52W High-5.49% Beta2.26
Dividend %- Quick Ratio16.90 Sales past 5Y- Gross Margin- 52W Low116.53% ATR3.73
Employees304 Current Ratio16.90 Sales Q/Q-33.30% Oper. Margin7.40% RSI (14)74.93 Volatility4.28% 6.77%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.30% Profit Margin15.70% Rel Volume0.93 Prev Close67.78
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume968.19K Price69.94
Recom2.20 SMA2023.77% SMA5043.69% SMA20035.13% Volume898,402 Change3.19%
Mar-05-20Initiated Stifel Hold $52
Feb-03-20Downgrade Evercore ISI Outperform → In-line $85 → $52
Nov-19-19Upgrade William Blair Mkt Perform → Outperform
Nov-12-19Upgrade Oppenheimer Perform → Outperform $65
Aug-01-19Initiated Jefferies Buy $64
Jul-26-19Initiated Canaccord Genuity Buy $72
Jun-10-19Initiated ROTH Capital Buy $50
Apr-12-19Initiated Evercore ISI Outperform
Mar-14-19Initiated William Blair Mkt Perform
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
May-15-18Reiterated Chardan Capital Markets Buy $25 → $72.50
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
May-19-20 05:09AM  Bull of the Day: Vertex Pharma (VRTX) Zacks
May-18-20 06:32PM  Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating Investor's Business Daily
May-16-20 10:00AM  2 Top Gene Editing Stocks to Watch in June Motley Fool
May-15-20 08:30AM  CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting GlobeNewswire +9.32%
May-14-20 09:02AM  New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress GlobeNewswire
07:10AM  News Flash: Analysts Just Made A Substantial Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts Simply Wall St.
May-12-20 03:40PM  Crispr Therapeutics Stock Jumps 15% In 2 Days After New Blood Disease Drug Fast-Tracked Investor's Business Daily
May-11-20 05:19PM  Why CRISPR Therapeutics Soared 13.8% Today Motley Fool +13.84%
09:00AM  CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the Treatment of Severe Hemoglobinopathies GlobeNewswire
May-07-20 08:00AM  CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference GlobeNewswire
May-05-20 08:00AM  These 3 Biotech Stocks Are Outperforming Their Peers Here's Why Investor's Business Daily
Apr-30-20 06:27AM  Better Buy: Crispr Therapeutics vs. bluebird bio Motley Fool -5.38%
Apr-28-20 07:45PM  CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:45PM  CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-27-20 12:31PM  Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for Zacks
12:00PM  What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock Zacks
Apr-24-20 11:41AM  7 Beautiful Biotech Stocks to Buy Here InvestorPlace
Apr-18-20 09:56AM  CRISPR Therapeutics AG's (NASDAQ:CRSP) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? Simply Wall St.
Apr-03-20 06:34PM  7 Biotech Stocks to Buy for a Post-Pandemic World
Mar-27-20 10:47AM  Hedge Funds Have Never Been This Bullish On CRISPR Therapeutics AG (CRSP) Insider Monkey
Mar-23-20 05:50PM  CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know Zacks
Mar-10-20 05:50PM  CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know Zacks
Mar-02-20 01:03AM  Horrible Week Finally Comes to an End Zacks
Feb-26-20 04:05PM  CRISPR Therapeutics Proposes Changes to the Board of Directors GlobeNewswire
Feb-19-20 07:59AM  Blood disorder startup files for $86M IPO American City Business Journals
Feb-13-20 08:05AM  The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO Benzinga
Feb-12-20 06:55PM  CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue Estimates Zacks
05:50PM  CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know Zacks
04:05PM  CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-11-20 02:26PM  CRISPR Therapeutics Shows Market Leadership With Jump To 92 RS Rating Investor's Business Daily
Feb-06-20 05:45PM  CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-04-20 02:56PM  Expand Your Portfolio with this First Profit Stock Screener Zacks
Jan-31-20 05:45PM  CRISPR Therapeutics AG (CRSP) Stock Moves -0.9%: What You Should Know Zacks
03:02PM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales Zacks
Jan-28-20 10:35AM  Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings? Zacks
05:26AM  Acceleron stock soars on lung drug trial data American City Business Journals
Jan-17-20 02:09PM  European ruling threatens Broad's CRISPR gene-editing patents American City Business Journals
Jan-14-20 05:11PM  SCANS: The FAANG of The Roaring 20s Zacks
Jan-10-20 09:42AM  The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk Zacks
Jan-09-20 03:20PM  SNACS: The FAANG Of The Roaring 20s Zacks
Jan-06-20 11:00PM  Crispr puts first human in-body gene editing to test Financial Times
04:05PM  CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference GlobeNewswire
11:32AM  These Top Fund Managers Outperform With Stocks That Many Other Investors Avoid Investor's Business Daily
Jan-03-20 05:50PM  CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know Zacks
09:15AM  Stocks Rally Into 2020 Zacks
Dec-30-19 04:07PM  Gene-Editing Stocks Dive As Creator Of CRISPR Babies Sent To Prison Investor's Business Daily -6.32%
03:40PM  Axsome Therapeutics jumps as migraine drug hits goals in late-stage trial Yahoo Finance Video
Dec-20-19 04:30PM  This CRISPR Stock Is A 2020 Top Pick But Will Gene Editing Succeed? Investor's Business Daily
11:50AM  This CRISPR Stock Is A 2020 Top Pick But Will Gene Editing Succeed? Investor's Business Daily
05:45AM  If You Had Bought CRISPR Therapeutics (NASDAQ:CRSP) Stock Three Years Ago, You Could Pocket A 212% Gain Today Simply Wall St.
Dec-11-19 03:41PM  What the Tech? Zacks
01:59PM  Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ? Insider Monkey
Dec-10-19 03:08PM  Find Strong Stocks Heading into 2020 with this First Profit Screen Zacks
Dec-04-19 05:31PM  Trade of the 2020's: Sell Gold, Buy Biotech Zacks
Dec-03-19 01:03AM  Don't Judge a Month by its First Day Zacks +6.57%
Nov-29-19 12:15PM  Biotech Tops in November: Best ETFs & Stocks Zacks +5.20%
11:30AM  The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG Zacks
Nov-27-19 05:33PM  Why Gold is Headed to Zero -- And What You Should Buy Instead Zacks
07:00AM  CRISPR Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-26-19 07:06PM  Why Biotech ETFs Surged in Monday's Trading Session Zacks
Nov-25-19 06:55PM  Genomics ETFs Surge on CRISPR's Gene Editing Progress Zacks +5.58%
Nov-22-19 03:12PM  Crispr Therapeutics Stock Surged; Was It A Sell? Investor's Business Daily
02:11PM  Consider Adding New Positions in U.S. Cannabis Stocks InvestorPlace
Nov-21-19 10:24AM  Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi Zacks -11.91%
07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-20-19 09:18PM  CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares GlobeNewswire
10:45AM  Crispr Therapeutics Rises After Company Announces Stock Sale
10:19AM  Company News For Nov 20, 2019 Zacks
09:31AM  Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More Zacks
09:12AM  Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data Zacks
07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga
01:05AM  The NASDAQ Needs No Break Zacks
Nov-19-19 05:20PM  Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug Investor's Business Daily +16.97%
04:28PM  Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug Investor's Business Daily
04:14PM  CRISPR Therapeutics Announces Proposed Public Offering of Common Shares GlobeNewswire
03:37PM  [video]Shares of CRISPR Therapeutics Fall in After Hours Trading on Share Offering
11:40AM  Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study Benzinga
11:25AM  Crispr Therapeutics Stock Spikes on Positive Gene-Editing Results
10:46AM  CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals
07:56AM  The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga
07:00AM  CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies GlobeNewswire
Nov-14-19 01:27PM  AMD, Amarin and Crispr are three stocks to watch for potentially higher prices MarketWatch
Nov-13-19 10:00AM  Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal Zacks
Nov-08-19 02:20PM  FDA approves Acceleron's blood disorder drug ahead of schedule American City Business Journals
Nov-04-19 05:05PM  15 Stocks With A High Current Ratio Benzinga
Oct-31-19 12:33PM  Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates Zacks
04:30AM  8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-29-19 04:05PM  Experts Talk Hot Biotech Stocks at Barrons Breakfast +9.07%
03:16PM  Investors Can Find Strong Stocks with our First Profit Screen Zacks
01:30PM  Boston firms return to Saudi conference after journalists murder American City Business Journals
Oct-28-19 02:58PM  BTIG: Crispr Could Be A Takeover Target For Vertex Benzinga +12.55%
08:15AM  CRISPR Therapeutics AG (CRSP) Q3 Earnings and Revenues Surpass Estimates Zacks
07:00AM  CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-25-19 12:06PM  Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings? Zacks
Oct-23-19 04:24PM  Navigating The Healthcare Industry: Science Fiction Turns to Reality Zacks
02:15PM  Is CRISPR Therapeutics AG (CRSP) Going To Burn These Hedge Funds ? Insider Monkey
Oct-16-19 10:13AM  CRISPR Therapeutics Enters New License Agreement, Shares Up Zacks
09:15AM  Earnings Season Makes Good First Impression Zacks
Oct-15-19 07:00AM  CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies Respective Cell Therapy Programs in Oncology GlobeNewswire
Oct-02-19 09:29AM  Vertex Enters Into Collaboration With Privately-Held Ribometrix Zacks
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni SamarthChief Executive OfficerMay 20Option Exercise1.8110,69319,354182,219May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 20Sale65.2810,693698,039171,526May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 19Option Exercise1.814,3077,796175,833May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 19Sale65.164,307280,644171,526May 21 04:35 PM
Novak RodgerPresidentMay 19Sale65.0050,0003,250,000798,007May 21 04:37 PM
Klein Lawrence OttoCBO & COOMay 11Option Exercise5.8625,000146,50045,000May 13 04:38 PM
Klein Lawrence OttoCBO & COOMay 11Sale60.4025,0001,509,97120,000May 13 04:38 PM
Kulkarni SamarthChief Executive OfficerDec 16Option Exercise1.818,00014,480172,320Dec 18 04:05 PM
CAGNONI PABLO JDirectorNov 19Option Exercise5.597,50041,9257,500Nov 21 04:07 PM
Novak RodgerPresidentNov 19Option Exercise14.4333,618485,10833,618Nov 21 04:09 PM
Bolzon Bradley J PhDDirectorNov 19Sale67.4128,2551,904,783596,741Nov 21 07:53 PM
Bolzon Bradley J PhDDirectorNov 19Sale67.4113,745926,6050Nov 21 07:53 PM
CAGNONI PABLO JDirectorNov 19Sale62.007,500465,0000Nov 21 04:07 PM
Novak RodgerPresidentNov 19Sale70.0033,6182,353,2600Nov 21 04:09 PM
CAGNONI PABLO JDirectorNov 12Option Exercise5.597,50041,9257,500Nov 13 04:30 PM
CAGNONI PABLO JDirectorNov 12Sale55.007,500412,5000Nov 13 04:30 PM
CAGNONI PABLO JDirectorOct 30Option Exercise5.597,50041,9257,500Nov 01 06:35 PM
CAGNONI PABLO JDirectorOct 30Sale52.007,500390,0000Nov 01 06:35 PM
Bolzon Bradley J PhDDirectorOct 30Sale51.8921,0001,089,67513,745Nov 01 06:34 PM
Klein Lawrence OttoChief Business OfficerJul 11Option Exercise5.868,42149,34728,421Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 11Sale50.018,421421,17120,000Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 10Option Exercise5.8611,57967,85331,579Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 10Sale50.0211,579579,18220,000Jul 12 04:13 PM
Novak RodgerPresidentJul 10Sale50.0050,0002,500,065848,007Jul 12 04:10 PM
Kulkarni SamarthChief Executive OfficerJun 17Option Exercise1.8120,00036,200185,801Jun 19 04:15 PM
Kulkarni SamarthChief Executive OfficerJun 17Sale46.0020,000920,000165,801Jun 19 04:15 PM
Novak RodgerPresidentJun 10Sale45.0050,0002,250,000898,007Jun 12 04:16 PM